Enterprise Therapeutics
Respiratory diseases drugs manufacturer
Enterprise Therapeutics has raised €30M across 2 funding rounds from 7 investors, most recently a Series B round in Jan 2024. Based in UK; active in Healthtech. Data as of 4 Nov 2026.
Total raised
€30M
€30,363,900
Funding rounds
2
Investors
7
distinct backers
Active since
2017-04
latest 2024-01
Funding by year
EUR raised per yearEnterprise Therapeutics — funding by year — interactive chart.
Data table
| Enterprise Therapeutics — funding by year | |
|---|---|
| 2017 | €0 |
| 2024 | €30M |
Signals
Medium confidenceRaise-next likelihood19
base rate 48% for Series B
- ▼ Past typical raise window
- ▼ Low backer re-investment
Exit likelihood9
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ 9y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-01-30 | Series B | €30M | Epidarex Capital,Forbion,IP Group,Novartis Venture Fund,Panakès Partners,Versant Ventures | View deal → |
| 2017-04-05 | Other | — | Cystic fibrosis Trust | View deal → |
Investors
7Related news
Similar companies
same sector, similar size- Enara Bio€29MUK · Healthtech
- Cn Bio Innovations€28MUK · Healthtech
- SolasCure€30MUK · Healthtech
- Simple Life€30MUK · Healthtech
- PhoreMost€39MUK · Healthtech
- Patchwork Health€31MUK · Healthtech
Global coverage: FundingData